Introduction
Streptococcus pneumoniae remains the leading bacterial aetiology of community-acquired pneumonia, acute sinusitis and bacterial meningitis. [1] [2] [3] [4] While the prevalence of this organism has long been recognized, new concern has been generated by the increasing worldwide frequency of penicillin non-susceptible isolates. [5] [6] [7] Currently in the USA the reported frequency of S. pneumoniae with reduced sensitivity to penicillin is around 24-34%. 5, 8 As a result of the prevalence of this pathogen and the change in susceptibility to routinely used antimicrobials, there may be a need for a change in current treatment practices. 9 Fluoroquinolone antibiotics are typically known for their excellent activity against Gram-negative pathogens. However, extended-spectrum fluoroquinolones with potent Gram-positive activity, such as trovafloxacin, have only recently become available. Trovafloxacin, a unique, synthetic fluoroquinolone with a long half-life, is characterized by its microbiological activity against anaerobes, Gram-negative and Gram-positive pathogens, including penicillin non-susceptible pneumococci. 10 Typical MIC values of trovafloxacin for S. pneumoniae are between four-and 32-fold lower than those reported for other fluoroquinolones such as ciprofloxacin and ofloxacin. 11, 12 The purpose of this study was to compare the protective effects of trovafloxacin, ciprofloxacin and ampicillin against penicillin-susceptible, -intermediate and -resistant isolates of S. pneumoniae using an intraperitoneal, immunocompetent mouse model of sepsis.
Materials and methods
Approval for all study methods and procedures was obtained from the Institutional Animal Care Use Committee prior to study initiation.
Protective effect of trovafloxacin, ciprofloxacin and ampicillin against
Streptococcus pneumoniae in a murine sepsis model 
Bacterial strains and susceptibility testing
Thirteen S. pneumoniae clinical isolates from Hartford Hospital and three isolates from Pfizer Laboratories were screened for susceptibility to penicillin, ampicillin, ciprofloxacin and trovafloxacin. MICs were determined in duplicate according to the National Committee for Clinical Laboratory Standards (NCCLS) using a microdilution technique and antimicrobial standard powders with known potencies. 13 Cation-adjusted Mueller-Hinton broth (CAMHB, Becton Dickinson, Cockeysville, MD, USA) supplemented with 2.5-5% lysed horse blood (LHB, Remel, Lenexa, KS, USA) was used as the bacterial growth medium in all in-vitro studies. Three isolates were selected which displayed a range of susceptibility for penicillin and ampicillin: one strain each of penicillin-susceptible, -intermediate and -resistant S. pneumoniae.
Antibiotics
The following antibiotics were used in all in-vivo studies: ampicillin sodium salt standard powder (Sigma Chemical Company, St Louis, MO, USA (lot 076H0373)), ciprofloxacin iv injection, 40 g/L (Bayer Corporation, West Haven, CT, USA (lot 6LCA)) and trovafloxacin standard powder (Pfizer Laboratories, New York, NY, USA (lot 31075-199-1F)).
Preparation of bacterial suspensions
Fresh colonies of the test isolates were taken from tryptocasein-soy agar plates (100 mm) with 5% sheep blood (Becton Dickinson) after overnight growth and inoculated into CAMHB with LHB. The bacterial suspension was placed into a 5% CO 2 incubator for 4 h before the start of all experiments. Colony forming unit (cfu) counts were verified by plating serially diluted aliquots on agar plates.
Animals
Immunocompetent Swiss Webster mice (Taconic Laboratory Animals and Services, Germantown, NY, USA) weighing approximately 25 g were used throughout this study. Animals were allowed, at least 72 h after delivery, to acclimatize to laboratory surroundings before experimentation.
Minimum lethal dose determination
The minimum lethal dose (MLD) was determined in duplicate for each study isolate. Groups of mice (n 10) were injected ip with 0.5 mL of inocula ranging from 10 1 to 10 7 cfu/mL. The MLD inoculum was selected on the basis of 100% mortality at the end of 48 h. For each MLD determination, a control group of 10 mice received normal saline instead of the bacterial suspension.
Protective dose determination
The protective dose for 50% of the population (PD 50 ) was determined in triplicate for each isolate over a 5 day study period. Groups of mice (n 10) were infected ip with 0.5 mL of the test isolate MLD bacterial suspension. The mean weight of the animal population was determined within the immediate 24 h period before bacterial infection. Using the mean population weight, dose-ranging studies were performed. Antibiotic solutions were serially diluted and prepared such that 0.2 mL would contain the following range of concentrations: trovafloxacin 0.5-32 mg/kg, ciprofloxacin 1-64 mg/kg and ampicillin 0.25-128 mg/kg. Antibiotics were administered as a single sc dose at the dorsal base of the neck 1 h after inoculation with bacteria. A group of 10 mice served as control for each experiment and received 0.2 mL of normal salineinstead of antibiotic.
Determination of activity
Animals were observed a minimum of three times daily over a 5-day period after inoculation. The PD 50 was calculated from the plot of survivors versus dose administered for each experiment using the Sigmoid E max model. 14 
Statistical analysis
Protective dose data were compared between antimicrobials for each isolate using an analysis of variance method followed by the Scheffe test for multiple comparisons. A P-value of 0.05 was considered significant.
Results

Susceptibility testing
The 
Minimum lethal dose determinations
Mortality was not observed in any of the control groups at 48 h during any of the MLD determinations. The virulent study isolates had MLD values ranging from 10 2 (SP22 and SP45) to 10 4 (SP46) cfu/mL as shown in the Table.
Protective dose determinations
Plots of percentage survival versus dose (mg/kg) are shown in Figures 1-3 
Discussion
The dose required to produce a survival rate of 50% with ampicillin against both the penicillin-susceptible and -intermediate strains was significantly lower when compared with trovafloxacin and ciprofloxacin. However, against the penicillin-resistant isolate ampicillin displayed poor activity, as was expected by its MIC value of 16 mg/L. Ciprofloxacin displayed poor in-vivo activity against all 479 study isolates as shown by the significantly higher PD 50 values compared with both ampicillin and trovafloxacin. Trovafloxacin produced the desired protective value with significantly lower dose when compared with ciprofloxacin against all tested isolates. Additionally, it displayed more potent activity against the penicillin-resistant strains compared with both ampicillin and ciprofloxacin. The trovafloxacin PD 50 value for SP22 was approximately twice that for either SP45 or SP46. This may be explained by the slightly higher MIC values for SP22 (MIC 0.125 mg/L) which was one dilution higher than the MIC value for SP45 or SP46 (MIC 0.06 mg/L).
The observed differences in microbiological activity between trovafloxacin and ciprofloxacin against S. pneumoniae may be due to an additional enzyme target for trovafloxacin. 10 Trovafloxacin has been found to inhibit both DNA gyrase and another type II topoisomerase, topoisomerase IV. The inhibition of topoisomerase IV is thought to confer enhanced potency against Gram-positive pathogens, such as S. pneumoniae.
Our group has previously shown that significantly lower PD 50 values are observed for penicillin G compared with ciprofloxacin when using a similar murine model of pneumococcal sepsis. 15 In this study, a penicillin-susceptible strain of S. pneumoniae was used with MICs of penicillin G and ciprofloxacin of 0.03 mg/L and 1.0 mg/L, respectively. The reported PD 50 of penicillin G was 0.307 0.325 mg/kg, and for ciprofloxacin it was 25.52 1.95 mg/kg. The PD 50 of ciprofloxacin was lower than the values observed in our present study, but in the study of Sullivan and colleagues, the animals received ciprofloxacin doses every 3 h for a total of eight doses. Additionally, in our study, all of the test strains had ciprofloxacin MIC values of 2 mg/L, which was higher than the MIC value of 1 mg/L used in the multidose ciprofloxacin study.
The activity of trovafloxacin and ciprofloxacin against S. pneumoniae has been evaluated in other in-vivo models including a rabbit model of meningitis, 16, 17 a systemic (intraperitoneal) sepsis model 18 and a murine pneumonia model. 18, 19 Regardless of the model investigated, trovafloxacin has consistently been shown to be more active against pneumococcus than other fluoroquinolones, including ciprofloxacin.
Our results seem to correlate well with previously published reports of trovafloxacin efficacy and ciprofloxacin failure against S. pneumoniae in other in-vivo models. [16] [17] [18] [19] The effects of trovafloxacin against penicillinresistant strains of S. pneumoniae may add to its clinical usefulness as penicillin resistance increases worldwide.
In summary, using a murine model of intraperitoneal sepsis, we have demonstrated that trovafloxacin has potent microbiological activity against S. pneumoniae compared with ciprofloxacin, regardless of penicillin susceptibility. However, when considering penicillin-susceptible and -intermediate strains, ampicillin displayed superior activity compared with trovafloxacin and ciprofloxacin.
